CIK 0001488039 · Non-accelerated filer<br>Smaller reporting company
ATOSSA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ATOS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 264753208
- Phone
- 206.588.0256
- Business address
- 1448 NW MARKET STREET, SUITE 500, SEATTLE, WA, 98107
- Former names
- ATOSSA GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-05-06 | Remmel H. Lawrence Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2014-05-06 | QUAY STEVEN C CEO | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2014-05-06 | WEAVER GREGORY L Director | Returned to the company | −24,510 | 0 | ||
| 2014-05-06 | WEAVER GREGORY L Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2014-05-06 | Steinhart Richard I Director | Returned to the company | −22,728 | 0 | ||
| 2014-05-06 | Steinhart Richard I Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2014-04-01 | Chen Ben R Sr. VP of Glob. Reg. Affairs | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2014-03-01 | Steinhart Richard I Director | Grant or award | +22,728 | 22,728 | ||
| 2014-03-01 | Steinhart Richard I Director | Grant or award · Stock Option (Right to Buy) | +16,484 | 16,484 | ||
| 2014-01-08 | Guse Kyle CFO & General Counsel | Grant or award · Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2013-11-21 | WEAVER GREGORY L Director | Purchase | +10,000 | $2.58 | $26K | 34,510 |
| 2013-10-10 | WEAVER GREGORY L Director | Grant or award | +24,510 | 24,510 | ||
| 2013-10-10 | WEAVER GREGORY L Director | Grant or award · Stock Option (right to buy) | +57,190 | 57,190 | ||
| 2013-10-01 | QUAY STEVEN C CEO | Sale | −7,265 | $5.66 | $41K | 4,268,315 |
| 2013-10-01 | Chen Shu-Chih Chief Scientific Officer | Sale | −7,265 | $5.66 | $41K | 4,268,315 |
| 2013-06-04 | Guse Kyle CFO & General Counsel | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2013-05-15 | CROSS ALEXANDER D Director | Purchase | +500 | $5.49 | $3K | 88,866 |
| 2013-05-07 | Galli Stephen J Director | Grant or award · Stock Option (right to buy) | +40,030 | 40,030 | ||
| 2013-05-07 | Galli Stephen J Director | Grant or award · Stock Option (right to buy) | +40,030 | 40,030 | ||
| 2013-05-07 | CROSS ALEXANDER D Director | Grant or award · Stock Option (right to buy) | +41,243 | 41,243 |
Page 8 of 9 · 168 trades